Back to top
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
biotechs: Archive
Kodiak (KOD) Q1 Loss Narrower Than Expected, Pipeline in Focus
by Zacks Equity Research
Kodiak (KOD) reports better-than-expected first-quarter 2024 results and provides updates regarding its pipeline development plans.
LGNDNegative Net Change ANIPNegative Net Change KODNo Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Vanda (VNDA) Rises on Positive Data From Motion Sickness Study
by Zacks Equity Research
Vanda's (VNDA) tradipitant appears effective in preventing vomiting associated with motion sickness in a second phase III study. Stock rises on the news.
LGNDNegative Net Change VNDAPositive Net Change ANIPNegative Net Change ENTXNegative Net Change
biotechs
Roche (RHHBY) Posts Encouraging Phase I Obesity Drug Data
by Zacks Equity Research
Data from the study shows that nearly half of the patients who received Roche's (RHHBY) subcutaneously-administered obesity drug lost more than 20% of their body weight after 24 weeks.
RHHBYPositive Net Change NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change
biotechs medical pharmaceuticals
Bristol Myers (BMY) Gets FDA Nod for Breyanzi Label Expansion
by Zacks Equity Research
Bristol Myers Squibb (BMY) obtains FDA approval for the label expansion of CAR T cell therapy Breyanzi to treat adult patients with relapsed or refractory follicular lymphoma.
BMYNegative Net Change LGNDNegative Net Change ANIPNegative Net Change TSVTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
by Zacks Equity Research
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
BIIBNegative Net Change LLYNegative Net Change THRDPositive Net Change
biotechs
Should You Hold Viking Therapeutics (VKTX) in Your Portfolio?
by Zacks Equity Research
Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
by Zacks Equity Research
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
LGNDNegative Net Change ANIPNegative Net Change HRTXPositive Net Change ASNDNegative Net Change
biotechs medical
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
by Zacks Equity Research
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.
UTHRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change ALLOPositive Net Change
biotechs cell-therapy earnings medical pharmaceuticals
Novo Nordisk (NVO) Up 3% as Haemophilia Drug Meets Study Goals
by Zacks Equity Research
Novo Nordisk's (NVO) shares rise 3.1% as the company meets co-primary endpoints in a late-stage study evaluating its investigational candidate, Mim8, for the treatment of haemophilia A.
NVONegative Net Change LGNDNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales
by Zacks Equity Research
Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.
REGNNegative Net Change JNJPositive Net Change BAYRYNegative Net Change LGNDNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Novavax (NVAX) Q1 Earnings Miss, Stock Soars on Sanofi Deal
by Zacks Equity Research
Novavax (NVAX) partners with Sanofi to market its COVID-19 vaccine and also develop novel COVID-19-influenza combination vaccines. This announcement even overshadows the dismal Q1 results.
SNYNegative Net Change PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs earnings medical vaccines
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
by Zacks Equity Research
Moderna's (MRNA) RSV vaccine, mRNA-1345's review timeline gets delayed. A decision is now expected by the end of May.
GSKNegative Net Change PFEPositive Net Change MRNAPositive Net Change LGNDNegative Net Change
biotechs
Bristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
AZNPositive Net Change BMYNegative Net Change MRKNegative Net Change LGNDNegative Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
bluebird (BLUE) Tops on Q1 Sales, Zynteglo Progresses Well
by Zacks Equity Research
bluebird (BLUE) beats sales estimates in the first quarter on increased Zynteglo product revenues. The company is on track with the ongoing launch of its gene therapies.
VRTXPositive Net Change HTGCNegative Net Change BLUENegative Net Change CRSPNegative Net Change
biotechs earnings gene-therapy pharmaceuticals
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nektar (NKTR) reports a narrower-than-expected loss in the first quarter of 2024 and tops revenue estimates.
NKTRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change
biotechs
Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Intellia's (NTLA) earnings and revenues surpass estimates in the first quarter of 2024. The company provides developmental and regulatory updates on its pipeline candidates. Stock rises.
REGNNegative Net Change NTLANegative Net Change ENTXNegative Net Change THRDPositive Net Change
biotechs earnings
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
by Zacks Equity Research
Insmed (INSM) Q1 earnings beat estimates while sales miss the mark. Management posts positive data readouts from mid-stage studies on its experimental inhalation powder in PH-ILD and PAH indications.
UTHRNegative Net Change LGNDNegative Net Change INSMPositive Net Change ANIPNegative Net Change
biotechs earnings medical
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
by Zacks Equity Research
Iovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for the recently-approved melanoma drug Amtagvi in the United States.
UTHRNegative Net Change LGNDNegative Net Change ANIPNegative Net Change IOVANegative Net Change
biotechs cell-therapy medical
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
by Zacks Equity Research
Amicus (FOLD) reports first-quarter 2024 results, wherein earnings beat the Zacks Consensus Estimate but sales miss the same. The company updates its financial guidance for 2024.
LGNDNegative Net Change FOLDNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
NBIXNegative Net Change ANIPNegative Net Change XENENegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Editas (EDIT) Q1 Earnings & Revenues Lag Estimates, Stock Down
by Zacks Equity Research
Editas (EDIT) reports weaker-than-expected first-quarter 2024 results as both earnings and revenues fall shy of estimates. Shares fall.
VRTXPositive Net Change LGNDNegative Net Change EDITNegative Net Change ENTXNegative Net Change
biotechs earnings
Prothena (PRTA) Q1 Earnings Miss Estimates on Higher R&D Expenses
by Zacks Equity Research
Prothena (PRTA) posts a wider-than-expected loss in the first quarter on lower revenues and higher costs.
RHHBYPositive Net Change BMYNegative Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs earnings pharmaceuticals
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.
LGNDNegative Net Change ENTXNegative Net Change MIRMNegative Net Change THRDPositive Net Change
biotechs earnings
Catalyst (CPRX) Q1 Earnings Beat, Firdapse Sales Drive Revenues
by Zacks Equity Research
Catalyst (CPRX) reports first-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, driven by strong Firdapse sales.
LGNDNegative Net Change CPRXNegative Net Change ANIPNegative Net Change ANVSNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
CRISPR's (CRSP) Q1 Loss Narrower-Than-Expected, Sales Miss
by Zacks Equity Research
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
VRTXPositive Net Change UTHRNegative Net Change LGNDNegative Net Change CRSPNegative Net Change
biotechs cell-therapy crispr earnings gene-editing gene-therapy immuno-therapy medical pharmaceuticals